Advertisement
Advertisement

SNDX

SNDX logo

Syndax Pharmaceuticals, Inc.

19.98
USD
Sponsored
+0.37
+1.89%
Jun 24, 16:00 UTC -4
Closed
exchange

After-Market

19.96

-0.02
-0.08%

SNDX Earnings Reports

Positive Surprise Ratio

SNDX beat 30 of 41 last estimates.

73%

Next Report

Date of Next Report
Aug 03, 2026
Estimate for Q2 26 (Revenue/ EPS)
$80.86M
/
-$0.48
Implied change from Q1 26 (Revenue/ EPS)
+24.66%
/
--
Implied change from Q2 25 (Revenue/ EPS)
+113.02%
/
-42.17%

Syndax Pharmaceuticals, Inc. earnings per share and revenue

On Apr 30, 2026, SNDX reported earnings of -0.48 USD per share (EPS) for Q1 26, beating the estimate of -0.59 USD, resulting in a 19.15% surprise. Revenue reached 64.86 million, compared to an expected 71.85 million, with a -9.72% difference. The market reacted with a -10.83% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 8 analysts forecast an EPS of -0.48 USD, with revenue projected to reach 80.86 million USD, implying an increase of 0.00% EPS, and increase of 24.66% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
enGene Therapeutics Inc. Common Stock
Report Date
Jun 15, 2026 For Q2 26
Estimate
-$0.47
Actual
-$0.43
Surprise
+10.32%
logo
Prenetics Global Limited Class A Ordinary Share
Report Date
Jun 10, 2026 For Q1 26
Estimate
-$1.10
Actual
-$1.61
Surprise
-45.36%
logo
Anixa Biosciences, Inc.
Report Date
Jun 10, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.07
Surprise
+21.61%
logo
Vistagen Therapeutics, Inc. Common Stock
Report Date
Jun 15, 2026 For Q4 26
Estimate
-$0.34
Actual
-$0.37
Surprise
-7.75%
FAQ
For Q1 2026, Syndax Pharmaceuticals, Inc. reported EPS of -$0.48, beating estimates by 19.15%, and revenue of $64.86M, -9.72% below expectations.
The stock price moved down -10.83%, changed from $21.43 before the earnings release to $19.11 the day after.
The next earning report is scheduled for Aug 03, 2026.
Based on 8 analysts, Syndax Pharmaceuticals, Inc. is expected to report EPS of -$0.48 and revenue of $80.86M for Q2 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement